Cart
Your cart is empty
Find
Carnitine shuttle substrate · β-oxidation carrier
Also known as Levocarnitine · L-(−)-carnitine
The endogenous quaternary ammonium compound that carries long-chain fatty acids into the mitochondrion for oxidation. Supplied as a lyophilized powder for research purposes only.
Launch Sale · Ends Nov 6
Tested lot by lot at ≥99% purity. The Janoshik certificate for your lot is emailed with the order.
Everything Valtrax Research ships is bench material for in-vitro work. None of it is a drug, a supplement, a cosmetic, or a medical device, and none of it is intended for human or animal use, ingestion, or administration. Placing an order is your confirmation that you are a qualified researcher buying for lawful research, under every Canadian law and regulation that applies to you.
Not a peptide. L-carnitine is a small zwitterionic quaternary ammonium compound, and its job in the cell is transport: long-chain fatty acids cannot cross the inner mitochondrial membrane as their CoA thioesters, so they are handed to carnitine first. That single constraint is why the molecule sits at the entrance to β-oxidation.
Worth naming what this is not — acetyl-L-carnitine. ALCAR carries an acetyl group and is studied largely for what that group does in the central nervous system. This vial is the free levo form, the carrier itself.
The question is almost always substrate flux: how fast a given cell moves long-chain fatty acids into the mitochondrion and oxidizes them, and what changes when that shuttle is loaded, blocked, or genetically removed. Skeletal muscle and cardiac tissue are the classical systems; cancer, immune, and stem-cell models are where the recent work sits.
The mechanism is a three-part shuttle. Carnitine palmitoyltransferase 1, on the outer mitochondrial membrane, transfers a long-chain acyl group from CoA onto carnitine; a translocase carries the resulting acylcarnitine across the inner membrane; CPT2 hands the acyl group back to CoA in the matrix, where β-oxidation takes it. CPT1 is the rate-limiting step, which is why so much fatty-acid-oxidation work is really CPT1 work.
Studies read the system through oxidation flux, acylcarnitine profiles, and muscle bioenergetics. The same shuttle keeps reappearing outside metabolism proper — in cancer cell biology, immune-cell fate, and stem-cell function — because whichever cell you are looking at, this is how it burns fat.
Carnitine was worked out as a metabolic carrier across the mid-twentieth century, and by the early 1980s the reviews had settled its role: Bremer’s account of carnitine metabolism and function, and Hoppel’s treatment of carnitine and carnitine palmitoyltransferase in fatty-acid oxidation and ketosis, are the reference points the field still cites.
The modern literature is less about the carrier and more about the enzymes that use it. CPT1 and CPT2 turned into targets and readouts in their own right, and carnitine became the reagent you need to study them.
In vitro and animal studies
L-carnitine is a quaternary ammonium compound, not a peptide, and its biochemistry is settled textbook material rather than an open research question. Its established role is in the carnitine shuttle: long-chain fatty acids must be conjugated to carnitine by carnitine palmitoyltransferase I to cross the inner mitochondrial membrane for beta-oxidation. Without carnitine, long-chain fat cannot be oxidised.
That mechanism is not in dispute, and it is the basis for the compound's legitimate clinical use in primary and secondary carnitine deficiency, where supplementation is genuinely corrective. Animal and cell work covers fatty acid oxidation rates, mitochondrial function, and effects in models of ischemia where fatty acid handling is disturbed.
The research question that remains open is not whether carnitine performs this function — it does — but whether adding carnitine to a system that already has sufficient carnitine changes anything. In a non-deficient organism, the shuttle is generally not the rate-limiting step, which is the crux of the entire supplementation literature.
Human data, where it exists
L-carnitine has been studied in humans extensively, and the results are more mixed than either its advocates or its critics usually acknowledge. It is an established treatment for carnitine deficiency states, including in dialysis populations and certain metabolic disorders, where the evidence is strong because the deficiency is real.
In non-deficient people, trials of exercise performance, fat oxidation and weight reduction have produced small and inconsistent effects. Meta-analyses of weight-loss trials have reported modest average reductions, with substantial heterogeneity and questions about study quality. Work on muscle carnitine content showed that raising it requires sustained co-administration with carbohydrate to drive insulin-mediated uptake, because oral carnitine alone does not readily increase intramuscular stores.
Separate clinical literature covers cardiovascular endpoints, male fertility parameters and diabetic neuropathy, with varying quality and no consistent conclusion.
Common assertions, and what the record supports
The claim that L-carnitine is a fat burner rests on a correct mechanism and an incorrect inference. Carnitine is required for long-chain fatty acid oxidation, so more carnitine is assumed to mean more oxidation. In people who are not carnitine-deficient, the shuttle is not the limiting step, and the human trial data reflects that — effects on fat oxidation and body composition are small and inconsistent.
A second claim concerns injectable versus oral forms. Oral carnitine has low and saturable bioavailability, and injection bypasses that. This is pharmacologically true. It does not establish that raising plasma carnitine changes muscle carnitine content, which is the variable that matters and which the muscle-loading studies showed to be difficult to move.
The honest summary is that carnitine is well understood, safe in ordinary use, and considerably less effective as a body-composition agent than its mechanism superficially suggests.
Against the compounds it is most often confused with
L-carnitine is the outlier on the metabolic shelf. Semaglutide and retatrutide are engineered receptor agonists with major clinical programmes. 5-Amino-1MQ and SLU-PP-332 are early-stage small molecules with rodent-only data. L-carnitine is a normal metabolite, present in food and synthesised endogenously, with decades of human study behind it.
That difference cuts both ways. Its safety profile in ordinary use is far better characterised than anything else on the shelf, and its effect size for body composition is far smaller. It is the one compound here where the question is not whether it is dangerous or whether it works mechanistically, but whether adding more to an already-sufficient system accomplishes anything.
Against the mitochondrial compounds on the longevity shelf — MOTS-c, SS-31 — carnitine addresses substrate delivery into the mitochondrion, while those address the function and integrity of the organelle itself.
Adverse findings, toxicology gaps, material hazards
L-carnitine is generally well tolerated, and its adverse effect profile in ordinary supplementation is mild — gastrointestinal upset, and a characteristic fishy body odour at higher intakes caused by trimethylamine production.
The more substantive concern is the TMAO pathway. Gut microbiota metabolise carnitine to trimethylamine, which the liver oxidises to trimethylamine N-oxide. Elevated TMAO has been associated with cardiovascular risk in observational and mechanistic work, and carnitine intake has been shown to raise it, with the magnitude depending on the composition of an individual's gut flora. Whether this association is causal remains contested, but it is a real line of published research rather than a theoretical objection.
Interactions with thyroid hormone signalling have been reported, and carnitine has been studied as a peripheral antagonist of thyroid hormone action. Seizure threshold effects have been raised in specific populations.
Bench practice for this compound
L-carnitine is a stable, water-soluble small molecule and is considerably more robust than the lyophilized peptides in this catalogue. It does not require the anti-foaming reconstitution technique used for peptide material.
Store as directed on this page, keeping the container closed and protected from moisture — carnitine is hygroscopic and will take up water from the air, which affects mass-based measurement. Prepared solutions should be kept refrigerated and protected from light.
This summary describes published research. It is not a protocol, not a recommendation, and not a statement that this compound is safe or effective for any use. Not for human or animal use.
Bremer, J. (1983). Carnitine--metabolism and functions.
PubMedHoppel, CL. (1982). Carnitine and carnitine palmitoyltransferase in fatty acid oxidation and ketosis.
PubMedQu, Q. et al. (2016). Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer.
PubMedGnoni, A. et al. (2020). Carnitine in Human Muscle Bioenergetics: Can Carnitine Supplementation Improve Physical Exercise?
PubMedPereyra, AS. et al. (2024). Loss of mitochondria long-chain fatty acid oxidation impairs skeletal muscle contractility by disrupting myofibril structure and calcium homeostasis.
PubMedEvery lot is checked independently by Janoshik for identity, purity, and net content; that certificate is included with the order.
Janoshik Analytical, a laboratory Valtrax does not own, runs the testing — identity by mass spectrometry, purity by RP-HPLC at ≥99%, on the lot you receive.
Same Shelf
